Gordon Black is CEO and Founder of East West Capital Limited, an investment management company investing in early stage companies operating across the global life sciences industry.
He has extensive work experience in the U.S. and the Asia Pacific region for corporations including: Merrill Lynch Capital Markets, New York; E.I. Du Pont de Nemours & Co. Inc (global head office Wilmington Delaware and Asia Pacific) and Ipoh Limited, Sydney, Australia.
He currently serves on the Board at NexSteppe Inc. a US proprietary hybrid seed company developing sorghum energy crops for the global bio-energy industry. Prior to this he served on the Board of the ASX listed drug developer Arana Therapeutics Limited before this company was acquired by Cephalon Inc from the US in June 2009 for $334 million.
He has an MBA from The Wharton School of Business, University of Pennsylvania, and a Biochemistry/ Chemistry degree from the University of New South Wales, Sydney.